Jefferies Group’s Kalaris Therapeutics KLRS Stock Holding History

Jefferies Group’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-713	Closed	-$630K	–	2057
2020 Q4	$630K	Buy	+713	New	+$549K	0.01%	1065

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Jefferies Group's KLRS Position: Q1 2021 in Review

Jefferies Group sold out of Kalaris Therapeutics (KLRS) in Q1 2021, closing a stake of 713 shares — an estimated $630K sold.

Jefferies Group first reported a position in KLRS in Q4 2020 and held it in 1 quarter. The position peaked at $630K in Q4 2020. 75 funds tracked by Wall St. Rank hold KLRS as of Q1 2021.

Jefferies Group reported no remaining Kalaris Therapeutics position as of Q1 2021 after selling out during the quarter.
Jefferies Group sold 713 Kalaris Therapeutics shares in Q1 2021, an estimated $630K.
Jefferies Group first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 1 quarter.
Jefferies Group's Kalaris Therapeutics position peaked at $630K in Q4 2020.
75 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.